Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to the ...
Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.
A 2023 clinical trial found that stopping tirzepatide (the generic for ... with at least one weight-related condition, such as high blood pressure, heart disease, or obstructive sleep apnea.
Novo Nordisk is finally facing some major competition to its obesity franchise juggernaut, now that Eli Lilly’s rival therapy tirzepatide ... such as high blood pressure, high cholesterol ...
and high-sensitive C-reactive protein level in the blood were measured at enrollment and after 24 weeks and 52 weeks. The study found participants in the tirzepatide group had a reduced combined ...
People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial.
The research also identified changes in glycemic control and cardiometabolic components like lipids and blood pressure. The research found that tirzepatide was generally well-tolerated ...
Cardiometabolic Health Markers: In addition to weight and diabetes risk reduction, tirzepatide use improved several cardiometabolic markers, including waist circumference, blood pressure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback